LILLY FDA Approval NDA 021462

NDA 021462

LILLY

FDA Drug Application

Application #021462

Documents

Letter2004-02-05
Letter2004-08-25
Letter2009-07-08
Letter2011-11-22
Letter2011-11-22
Letter2011-03-23
Letter2012-10-18
Letter2013-09-13
Label2004-08-19
Label2006-08-04
Label2007-09-11
Label2009-07-09
Label2011-11-25
Label2012-10-17
Label2012-06-05
Label2013-09-17
Patient Package Insert2004-02-05
Other Important Information from FDA2005-04-15
Letter2006-08-04
Letter2007-02-12
Letter2007-09-11
Letter2008-10-01
Letter2009-07-08
Letter2009-07-08
Letter2011-11-22
Letter2012-06-07
Letter2012-11-14
Label2004-02-05
Label2007-02-21
Label2008-09-26
Label2009-07-06
Label2009-07-09
Label2011-11-23
Label2011-11-25
Label2011-03-21
Label2013-01-22
Label2012-11-15
Review2004-03-28
Review2011-09-22
Other2004-02-05
Label2017-10-12
Letter2017-10-12
Pediatric Medical Review1900-01-01
Pediatric Clinical Pharmacology Review1900-01-01
Pediatric Statistical Review1900-01-01
Letter2018-04-20
Label2018-06-05
Letter2018-06-05
Label2019-01-31
Letter2019-02-13
Pediatric Written Request1900-01-01
Pediatric Amendment 11900-01-01
Pediatric Amendment 21900-01-01
Pediatric Amendment 31900-01-01
Label2020-12-23
Letter2022-09-01
Label2022-09-01

Application Sponsors

NDA 021462LILLY

Marketing Status

Prescription001
Prescription002

Application Products

001POWDER;INTRAVENOUSEQ 500MG BASE/VIAL1ALIMTAPEMETREXED DISODIUM
002POWDER;INTRAVENOUSEQ 100MG BASE/VIAL1ALIMTAPEMETREXED DISODIUM

FDA Submissions

TYPE 1; Type 1 - New Molecular EntityORIG1AP2004-02-04PRIORITY
LABELING; LabelingSUPPL4AP2006-07-28STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL6AP2007-02-02N/A
MANUF (CMC); Manufacturing (CMC)SUPPL12AP2007-09-07N/A
EFFICACY; EfficacySUPPL15AP2008-09-26STANDARD
LABELING; LabelingSUPPL18AP2009-07-02STANDARD
EFFICACY; EfficacySUPPL21AP2009-07-02UNKNOWN
LABELING; LabelingSUPPL22AP2009-07-02STANDARD
EFFICACY; EfficacySUPPL29AP2011-11-18STANDARD
LABELING; LabelingSUPPL30AP2011-11-18UNKNOWN
LABELING; LabelingSUPPL32AP2011-11-18STANDARD
EFFICACY; EfficacySUPPL33AP2011-03-17PRIORITY
EFFICACY; EfficacySUPPL39AP2012-10-17STANDARD
LABELING; LabelingSUPPL40AP2012-06-04STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL41AP2013-03-13PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL42AP2013-01-18PRIORITY
LABELING; LabelingSUPPL43AP2012-11-09STANDARD
LABELING; LabelingSUPPL45AP2013-09-12STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL47AP2014-08-11PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL49AP2016-01-08PRIORITY
LABELING; LabelingSUPPL50AP2017-10-11STANDARD
EFFICACY; EfficacySUPPL51AP2018-06-04STANDARD
LABELING; LabelingSUPPL52AP2018-04-17STANDARD
EFFICACY; EfficacySUPPL53AP2019-01-30STANDARD
EFFICACY; EfficacySUPPL55AP2022-08-31STANDARD

Submissions Property Types

ORIG1Null2
SUPPL21Null6
SUPPL29Null7
SUPPL30Null7
SUPPL32Null7
SUPPL33Null8
SUPPL39Null7
SUPPL40Null7
SUPPL41Null14
SUPPL42Null14
SUPPL43Null6
SUPPL45Null15
SUPPL47Null14
SUPPL49Null14
SUPPL50Null7
SUPPL51Null7
SUPPL52Null15
SUPPL53Null7
SUPPL55Null7

TE Codes

001PrescriptionAP
002PrescriptionAP

CDER Filings

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 21462
            [companyName] => 
            [docInserts] => ["",""]
            [products] => []
            [labels] => 
            [originalApprovals] => []
            [supplements] => 
            [actionDate] => 0000-00-00
        )

)

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.